News

Check out our newsletter to read about FDA approval for the first-ever treatment for Progeria, learn how the research we fund has made remarkable progress toward the cure through genetic and RNA therapies, and get the scoop on all the exciting milestones we’re celebrating right now.

We’re thrilled to share that PRF has been awarded the highest 4-star Charity Navigator rating for our 8th straight year! CharityNavigator is the top evaluator of U.S.-based nonprofits, and this coveted 4-star rating is only awarded to 6% of the nonprofits evaluated....

In November, 2020, PRF brought over 370 registrants from 30 countries ‘together’ in our first-ever virtual scientific workshop. Attendees were given a platform to share their expertise in Progeria research and meet some of the children who will benefit from their work. A summary of the workshop was published today in the journal Aging.

We’re thrilled to share the results from two very exciting breakthrough studies on the use of RNA therapeutics in Progeria research. Both studies were co-funded by The Progeria Research Foundation (PRF) and co-authored by PRF’s Medical Director, Dr. Leslie Gordon.

In January, the science journal Nature published breakthrough results demonstrating that genetic editing in a mouse model of Progeria corrected the mutation that causes Progeria in many cells, improved several key disease symptoms and dramatically increased lifespan in the mice.

We’re thrilled to announce that today, we achieved an important piece of PRF’s mission: lonafarnib, the first-ever treatment for Progeria, has been granted FDA approval.

Read about how our progress continues despite the pandemic; the science driving PRF’s latest grant recipients to propel Progeria research to new heights; inspiring thoughts from families in our Progeria community; and so much more.